Metagenomic analysis of intestinal microbiota in hematologic malignancies and development of disease risk and prognostic models.

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K17401
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Osaka University
• Principal Investigator: Shinsuke Kusakabe 大阪大学, 大学院医学系研究科, 助教 (50747186)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 腸内細菌叢 / 同種造血幹細胞移植 / 腸球菌 / 慢性GVHD / 晩期合併症

Outline of Final Research Achievements

Abnormalities in the intestinal microbiota have been reported to be associated with various complications and transplantation outcomes in the field of HSCT. We collected fecal samples from allogeneic hematopoietic stem cell transplant recipients over time and analyzed the correlation between abnormalities in the intestinal microbiota and complications after transplantation. In 2020 we reported that gut microbiota abnormalities persisted over 1 year after the transplantation in allogeneic transplantation recipients and that the relative abundance of Enterococcus at 1 month after the transplantation was associated with post-transplant survival. In 2021, in collaboration with the Department of Hematology, Tokyo Metropolitan Komagome Hospital, we reported the association between abnormalities of gut microbiota and chronic GVHD.In 2022, we reported the association between the gut persistent abnormalities of gut microbiota and complications in long-term post-transplant survivors.

Free Research Field

血液学

Academic Significance and Societal Importance of the Research Achievements

2020年の論文では腸球菌の増加が移植後生存の予測因子になりうることを示した。2021年の論文では移植後の腸内細菌叢の多様性が慢性GVHDの発症予測因子になりうることを示した。これらの成果は、移植後の生存、合併症の予測モデルを構築するうえで重要な情報となる。また、2022年の論文では移植後長期生存者における腸内細菌叢の異常を報告した。移植後の晩期合併症はこれまでほとんど研究データがなく、発症予測、予防や治療に難渋することが多かったが、本研究の知見をもとに病態解明のための新たな道筋が開けるものと考える。